The Drug Pricing Paradox: Why American Patients Keep Paying More

At some point in almost every discussion about American healthcare, someone reaches for a grocery store analogy. Mark Cuban, entrepreneur, pharmacy disruptor, and one of the more credible voices in the drug pricing debate, has a characteristically blunt version: Americans would never accept paying for potato chips the way they pay for prescription drugs. You would not tolerate a situation in which the price of a bag of crisps varied by a factor of ten depending on which supermarket you walked into, which loyalty card you held, or whether your employer had negotiated a volume rebate with a middleman whose fees were opaque and whose incentives were misaligned with yours.

Yet that is, with only modest exaggeration, precisely how the United States prices medication. And despite repeated presidential promises to fix it, from both parties, across multiple administrations, the structural incentives that sustain the system have proven remarkably durable. The latest attempt, anchored in the Trump administration's pledge to deliver lower drug prices, is already running into the institutional resistance that has defeated every predecessor.

The Promise and the Gap

Donald Trump made drug pricing a signature issue in both his first and second presidential campaigns. The rhetoric was sharp and the political positioning shrewd: attacking pharmaceutical companies plays well across partisan lines in a country where a significant share of voters report difficulty affording their medications. In his second term, the administration initially pursued a combination of executive actions and legislative pressure aimed at compelling manufacturers to lower list prices, with particular focus on insulin and other high-profile medications.

The results have been mixed at best. While some targeted interventions, notably limits on insulin pricing for certain Medicare beneficiaries, have delivered modest, visible relief, the broader architecture of American drug pricing has remained largely intact. And in some areas, Congressional action has actively worked against the stated presidential goal.

The central villain in the current chapter of this story is the pharmacy benefit manager, or PBM, a class of intermediary that sits between drug manufacturers, insurers, and pharmacies, theoretically negotiating lower prices on behalf of payers. In practice, PBMs have come under sustained criticism from economists, patient advocates, and independent investigators for operating in ways that can actually inflate net drug costs while extracting substantial fees for themselves.

How PBMs Became the Problem

The pharmacy benefit manager model emerged in the 1970s and 1980s as a sensible administrative solution: insurers needed someone to process drug claims efficiently and negotiate with manufacturers at scale. Over the following decades, the three largest PBMs, CVS Caremark, Express Scripts, and OptumRx, grew to control the majority of prescription drug transactions in the United States, creating a quasi-oligopoly with enormous leverage over every other participant in the market.

The mechanism by which PBMs extract value is complex and deliberately opaque, but the core dynamic is relatively straightforward. Manufacturers pay PBMs rebates, effectively kickbacks, in exchange for preferred placement on the formulary lists that determine which drugs insurers will cover and at what cost-sharing level for patients. The higher a drug's list price, the larger the potential rebate, which means PBMs have a structural incentive to favour high-list-price medications over cheaper alternatives, even when the cheaper alternative would serve the patient equally well.

This is the mechanism that Mark Cuban's Cost Plus Drugs venture has sought to disrupt by simply publishing transparent manufacturing costs and charging a fixed margin. The early results have been striking, some medications available through Cost Plus cost a fraction of their price at traditional pharmacies, and they illustrate how much of the gap between what drugs cost to make and what patients pay is attributable not to genuine value creation but to layers of intermediary extraction.

Congress Complicates the Cure

The Trump administration's original legislative agenda included meaningful PBM reform, specifically, requirements for greater transparency in rebate flows and restrictions on the spread pricing practices that allow PBMs to charge payers more than they reimburse pharmacies, pocketing the difference. These reforms had bipartisan support in principle.

In practice, the legislative process has diluted, delayed, and in some cases reversed these provisions. Pharmaceutical industry lobbying expenditure in Washington remains among the highest of any sector, and PBMs, despite their lower public profile, are no less aggressive in protecting their revenue model. The result has been a series of compromises that preserve the appearance of reform while leaving the structural incentives largely undisturbed.

Some Congressional provisions recently enacted have, according to independent analyses, actually increased the incentive for manufacturers to raise list prices, because the rebate structures that underpin PBM revenue depend on list price inflation. This is the paradox at the heart of the current situation: political actors who sincerely want lower drug prices are operating within an institutional framework that systematically produces higher ones.

International Comparisons and the Structural Explanation

The United States is a consistent outlier in international drug pricing comparisons. Americans pay, on average, two to three times more for branded prescription drugs than patients in comparable wealthy nations, the United Kingdom, Germany, Canada, Japan. The gap cannot be explained by differences in manufacturing costs, which are largely global. It reflects, instead, a set of structural choices: the absence of a central government negotiating counterparty, the fragmentation of the insurance market, and the political power of the industries that benefit from the status quo.

European health systems, for all their inefficiencies, have one structural advantage in drug pricing that the United States conspicuously lacks: monopsony power. When a single national payer or regulator negotiates with a drug manufacturer, the manufacturer faces a binary choice between accepting a regulated price and losing access to the entire market. That leverage produces lower prices. The fragmented American system, thousands of insurers, PBMs, and hospital systems each negotiating separately, offers manufacturers the opportunity to price-discriminate, extract maximum value from each channel, and resist the transparency that would allow any participant to benchmark against the others.

What Genuine Reform Would Require

Structural drug pricing reform in the United States would require confronting several deeply entrenched interests simultaneously. It would mean meaningful PBM transparency requirements with actual enforcement mechanisms. It would require delinking PBM compensation from rebate volumes, eliminating the perverse incentive to favour high-list-price drugs. It would benefit from expanding the scope of Medicare's new drug negotiation authority, itself a modest but significant departure from previous policy, and from aggressive action against anti-competitive practices in the generic drug market, where price-fixing conspiracies have been documented and prosecuted but not eliminated.

None of these reforms is technically complicated. The economics are well understood, the policy designs are well developed, and the political rhetoric across both parties nominally supports the direction of travel. The obstacle is not intellectual, it is the organised resistance of industries whose revenue model depends on the perpetuation of a system that, as Mark Cuban's potato chip analogy implies, would not survive a moment's rational scrutiny if patients could see it clearly.

Until the incentive structures change, presidential promises about drug pricing will continue to collide with Congressional reality. And American patients will continue paying prices that no other wealthy country's citizens would tolerate.